FDA Approves Engineered Viral Immunotherapy for Treatment-Resistant Advanced Melanoma

Advanced melanoma that stops responding to PD-1 immunotherapy represents one of oncology's most difficult challenges. Until now, patients who progressed through first-line checkpoint inhibitors had extremely limited options, making the FDA's accelerated approval of Tudriqev a meaningful development for this underserved population.

Tudriqev (vusolimogene oderparepvec-wtpg) is a genetically engineered oncolytic therapy derived from herpes simplex virus type 1 (HSV-1). The virus is modified to selectively replicate inside tumor cells, destroying them from within while releasing signals that recruit the immune system to recognize and attack the cancer. When combined with nivolumab — itself a PD-1 blocking antibody — the combination may help overcome the immune evasion mechanisms that made the cancer resistant to prior therapy.

The pivotal trial enrolled 140 adult patients with Stage IIIB, IIIC, or IV unresectable melanoma who had progressed on at least eight weeks of prior anti-PD-1-based therapy. Among 91 evaluable patients, 24% achieved an objective response, with a median response duration of 14.1 months. These numbers, while modest, are clinically meaningful in a population with few alternatives.

Tudriqev is administered via direct intratumoral injection every two weeks for eight doses, with a lower concentration used for the first dose. Nivolumab is added intravenously beginning at week three. Common side effects include fatigue, fever, chills, nausea, and injection site reactions. A significant safety concern is the potential for herpes virus transmission to close contacts, requiring careful patient education and precautions.

The accelerated approval pathway means Tudriqev must still confirm clinical benefit in further trials. For clinicians and patients navigating post-immunotherapy melanoma, however, this represents a real, if early-stage, advance in a field where options have been critically scarce.